Concomitant Delivery of Doxorubicin and Cisplatin Through Liposome-based Thermosensitive Nanoparticles: Perspective in the Treatment of Cancer in Animal Models

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2023 Mar 10

PMID 36895979

Authors

Hamzah M Maswadeh

Arif Khan

Mohammed S Alorainy

Naser A Al-Wabel

Costas Demetzos

Affiliations

Soon will be listed here.

Abstract

The temperature sensitive liposomal formulations are a promising tool to improve the therapeutic index of the drugs with minimal toxicity. The aim of this study was to investigate the potential of concomitant delivery of cisplatin (Cis) and doxorubicin (Dox) containing thermosensitive liposomes (TSLs) with mild hyperthermia against cancer and . The polyethylene glycol coated DPPC/DSPC, thermosensitive and DSPC, non-thermosensitive liposomes incorporating Cis and Dox were prepared and characterized. A conventional Differential Scanning Calorimetry (DSC) technique and Fourier Transform Infrared Spectroscopy (FT-IR) were applied to study drug-phospholipid interaction and compatibility. The chemotherapeutic efficacy of these formulations was evaluated in benzo[a]pyrene (BaP) induced fibrosarcoma under hyperthermic condition. The size diameter of prepared thermosensitive liposomes was measured to be 120 ± 10 nm. The DSC data exhibited the changes in the curves of DSPC + Dox and DSPC + Cis while comparing the pure DSPC and drugs. However, the FITR showed same spectrum of phospholipids and drugs individually and in the mixture as well. The data showed higher efficacy of Cis-Dox-TSL as 84% inhibition in tumor growth was recorded in this group of animals in hyperthermic condition. The Kaplan-Meir curve revealed, 100% and 80% survival of the animals in the groups treated with Cis-Dox-TSL under hyperthermia and Cis-Dox-NTSL without hyperthermia, respectively. However, Cis-TSL as well as Dox-TSL exhibited 50% survival, while only 20% survival was recorded in the groups of animals treated with Dox-NTSL and Cis-NTSL. The flow cytometry analysis revealed that Cis-Dox-NTSL augments the induction of apoptosis in the tumor cells which was recorded as 18%. As expected, Cis-Dox-TSL showed great potential as 39% of cells were measured as apoptotic cells, significantly very high in comparison to Cis-Dox-NTSL, Dox-TSL and Cis-TSL as well. The apoptotic analysis of the cells by flow cytometry clearly indicated the effect of hyperthermia during the treatment while Cis-Dox-TSL formulation was administered. Finally, the immunohistochemical analysis of the tumor tissues by confocal microscopy exhibited several fold increases in the expression of pAkt in the animals treated with vehicles in Sham-NTSL as well as Sham-TSL. However, Cis-Dox-TSL showed great reduction in the expression of Akt, as it declined by 11-fold. The results of the present study directed the role of concomitant delivery doxorubicin and cisplatin containing thermosensitive liposomes under hyperthermic conditions for the development of a novel therapeutic strategy for the treatment of cancer.

Citing Articles

Combination Therapy of Curcumin and Cisplatin Encapsulated in Niosome Nanoparticles for Enhanced Oral Cancer Treatment.

Saberian E, Jencova J, Jenca A, Petrasova A, Jenca J, Akbarzadehkhayavi A Indian J Clin Biochem. 2025; 40(1):59-66.

PMID: 39835233 PMC: 11741963. DOI: 10.1007/s12291-024-01279-9.

Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice.

Aloss K, Bokhari S, Leroy Viana P, Giunashvili N, Schvarcz C, Szenasi G Int J Mol Sci. 2024; 25(6).

PMID: 38542073 PMC: 10970314. DOI: 10.3390/ijms25063101.

Preparation, characterization, and Co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer Activities.

Bahrami Parsa M, Tafvizi F, Chaleshi V, Ebadi M Heliyon. 2023; 9(10):e20657.

PMID: 37818003 PMC: 10560846. DOI: 10.1016/j.heliyon.2023.e20657.

References

Li Y, Xu P, He D, Xu B, Tu J, Shen Y . Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin. Int J Nanomedicine. 2020; 15:6721-6734. PMC: 7494235. DOI: 10.2147/IJN.S250773. View

Li S, Yin G, Pu X, Huang Z, Liao X, Chen X . A novel tumor-targeted thermosensitive liposomal cerasome used for thermally controlled drug release. Int J Pharm. 2019; 570:118660. DOI: 10.1016/j.ijpharm.2019.118660. View

Khan A, Alsahli M, Aljasir M, Maswadeh H, Mobark M, Azam F . Safety, Stability, and Therapeutic Efficacy of Long-Circulating TQ-Incorporated Liposomes: Implication in the Treatment of Lung Cancer. Pharmaceutics. 2022; 14(1). PMC: 8778344. DOI: 10.3390/pharmaceutics14010153. View

Bedard P, Hyman D, Davids M, Siu L . Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020; 395(10229):1078-1088. DOI: 10.1016/S0140-6736(20)30164-1. View

Sobczuk P, Czerwinska M, Kleibert M, Cudnoch-Jedrzejewska A . Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2020; 27(1):295-319. PMC: 8739307. DOI: 10.1007/s10741-020-09977-1. View

Song M, Bode A, Dong Z, Lee M . AKT as a Therapeutic Target for Cancer. Cancer Res. 2019; 79(6):1019-1031. DOI: 10.1158/0008-5472.CAN-18-2738. View

Edwardson D, Narendrula R, Chewchuk S, Mispel-Beyer K, Mapletoft J, Parissenti A . Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines. Curr Drug Metab. 2015; 16(6):412-26. PMC: 5398089. DOI: 10.2174/1389200216888150915112039. View

Katzenstein H, Malogolowkin M, Krailo M, Piao J, Towbin A, McCarville M . Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study. Cancer. 2021; 128(5):1057-1065. PMC: 9066555. DOI: 10.1002/cncr.34014. View

Suk J, Xu Q, Kim N, Hanes J, Ensign L . PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2015; 99(Pt A):28-51. PMC: 4798869. DOI: 10.1016/j.addr.2015.09.012. View

10.

Khandelwal Gilman K, Han S, Won Y, Putnam C . Complex interactions of lovastatin with 10 chemotherapeutic drugs: a rigorous evaluation of synergism and antagonism. BMC Cancer. 2021; 21(1):356. PMC: 8022429. DOI: 10.1186/s12885-021-07963-w. View

11.

Khan A, Alsahli M, Aljasir M, Maswadeh H, Mobark M, Azam F . Experimental and Theoretical Insights on Chemopreventive Effect of the Liposomal Thymoquinone Against Benzo[]pyrene-Induced Lung Cancer in Swiss Albino Mice. J Inflamm Res. 2022; 15:2263-2280. PMC: 9005154. DOI: 10.2147/JIR.S358632. View

12.

Wu H, Jin H, Wang C, Zhang Z, Ruan H, Sun L . Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery. ACS Appl Mater Interfaces. 2017; 9(11):9426-9436. DOI: 10.1021/acsami.6b16844. View

13.

de Matos M, Beztsinna N, Heyder C, Fens M, Mastrobattista E, Schiffelers R . Thermosensitive liposomes for triggered release of cytotoxic proteins. Eur J Pharm Biopharm. 2018; 132:211-221. DOI: 10.1016/j.ejpb.2018.09.010. View

14.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

15.

Santiago Franco M, Gomes E, Roque M, Oliveira M . Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment. Front Oncol. 2021; 11:623760. PMC: 8008067. DOI: 10.3389/fonc.2021.623760. View

16.

Ta T, Porter T . Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release. 2013; 169(1-2):112-25. PMC: 5127786. DOI: 10.1016/j.jconrel.2013.03.036. View

17.

Sazonova E, Kopeina G, Imyanitov E, Zhivotovsky B . Platinum drugs and taxanes: can we overcome resistance?. Cell Death Discov. 2021; 7(1):155. PMC: 8257727. DOI: 10.1038/s41420-021-00554-5. View

18.

Alrbyawi H, Poudel I, Annaji M, Arnold R, Tiwari A, Jayachandra Babu R . Recent Advancements of Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery. Pharm Nanotechnol. 2022; 10(1):3-23. DOI: 10.2174/2211738510666220214102626. View

19.

Lee Y, Thompson D . Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017; 9(5). PMC: 5557698. DOI: 10.1002/wnan.1450. View

20.

Thigpen J, Brady M, Homesley H, Malfetano J, DuBeshter B, Burger R . Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004; 22(19):3902-8. DOI: 10.1200/JCO.2004.02.088. View